



DRUG DISCOVERY

Innovations in Protein Kinase Therapies

Company pipelines, therapeutic applications and market forecasts

By Biophoenix

Biophoenix

Biophoenix is a biomedical consultancy based in the heart of England, UK, which was founded by Dr Sreten Bogdanovic and Dr Beata Langlands. Established with support from the UK Department of Trade and Industry (DTI) in 1994, Biophoenix provides detailed, accurate, market and technical information to support decision-making by biotechnology-based enterprises in the healthcare industry. In doing so, Biophoenix relies on its comprehensive in-house bioindustry database and a wide network of contacts. Biophoenix also audits biotechnology-based enterprises with regard to the risk of intellectual property litigation on behalf of several Lloyds of London insurers. Further information is available on the internet at www.biophoenix.com.

Dr Bogdanovic is Managing Partner in Biophoenix. He holds a PhD in endocrinology from Imperial College, UK, and has worked as product manager for immunodiagnostics with the UK subsidiary of Boehringer Mannheim (now owned by Roche), and as an independent biomedical market analyst with Cistrion, UK. Dr Langlands holds a PhD in biochemistry from the University of Glasgow, UK, and has worked as an immunologist, a project leader with a new biotechnology company based at Warwick University in the UK, and as a university lecturer. Biophoenix has researched and written over 50 in-depth management/market reports.

Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any
purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of
Business Insights. Business Insights Ltd accepts no liability for the accuracy or
completeness of the information, advice or comment contained in this Management
Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of
publication, no responsibility can be accepted by Business Insights Ltd for its
completeness or accuracy.

Table of Contents

Kinases: Highways to Drug Discovery

Executive Summary **16**

Chapter 1 Kinases as drug targets	16
Chapter 2 Small molecule kinase inhibitor discovery	17
Chapter 3 Targeting kinases in cancer	18
Chapter 4 Non-cancer applications of kinase drugs	20
Chapter 5 Leading kinase drug originating companies	21
Chapter 6 Market Analysis: Trends and Forecasts	22

Chapter 1 Kinases as drug targets **26**

Summary	26
Introduction	27
Overview of human protein kinases	30
Classification schemes	32
Kinases in signal transduction pathways	36
MAPK pathways	38
MAPK (ERK) pathway	39
JNK/SAPK pathway	40
MAPK14 pathway	40
PI3K/AKT signaling	41
JAK/STAT signaling	41
NFKB pathway	42
Insulin receptor signaling	43
Immune cell signaling	43
T cell receptor signaling	43
B-cell receptor complexes	44
Signaling in vascular morphogenesis	44
VEGF receptor signaling	44
EGF receptor signaling	45
Cyclic nucleotide metabolism	45
Cell cycle checkpoint controls	45
Categories of kinase-targeted drugs	46
Small molecules	47
Monoclonal antibodies	49

Emerging biopharmaceuticals	50
Kinase drug audit	51
Chapter 2	Small molecule kinase inhibitor discovery
	58
Summary	58
Introduction	59
Mechanisms of kinase inhibition	60
ATP competitive inhibitors	60
Irreversible inhibitors	61
Allosteric inhibitors	62
Approaches to kinase inhibitor discovery	63
Traditional kinase inhibitor discovery	63
High-throughput screening of compound libraries	63
Lead optimization	65
Synthesis of inhibitor analogs	65
Structure-informed drug design	66
Structure-informed drug re-design	67
Fragment-based drug discovery	68
Kinase inhibitor selectivity assays	69
Protein selectivity assays	70
Kinase activity assays	70
Kinase binding assays	71
Cellular selectivity assays	73
Identifying substrates of kinases	74
Chapter 3	Targeting kinases in cancer
	78
Summary	78
Overview of cancer	79
Established and emerging therapies	84
Therapeutic potential of kinase inhibition	86
Types of kinase targets	89
Mutationally-activated kinases	89
Kinases which sustain tumor growth	90
Kinases with roles in tumorigenesis	91
Top 20 kinase targets	92
Group: TK	92
ABL1 (Abl family)	92
Target characteristics	92

	Inhibitors on the market	93
	Inhibitors in development	96
EGFR and ERBB2 (EGFR family)		101
	Target characteristics	101
	Approaches to EGFR inhibition	102
	Inhibitors on the market	104
	Inhibitors in development	107
FLT3, KIT, PDGFRA, and PDGFRB (PDGFR family)		117
	Target characteristics	117
	Inhibitors on the market	118
	Inhibitors in development	119
FLT1, FLT4, and KDR (VEGFR family)		136
	Target characteristics	136
	Inhibitors on the market	137
	Inhibitors in development	138
JAK2 (JAK family)		152
	Target characteristics	152
	Drugs in development	152
MET (Met family)		155
	Target characteristics	155
	Agents in development	155
Group: AGC		158
AKT1 (AKT family)		158
	Target characteristics	158
	Drugs in development	158
Group: CMGC		161
CDC2 and CDK2 (CDK family; CDC2 subfamily)		161
	Target characteristics	161
	Drugs in development	161
Group: Other		165
AURKA and AURKB (AUR family)		165
	Target characteristics	165
	Drugs in development	165
PLK1 (PLK family)		169
	Target characteristics	169
	Drugs in development	169
Group: Atypical		171
	Target characteristics	171
	Inhibitors on the market	171
	Inhibitors in development	172
Dual specificity lipid/protein kinases		176
PIK3CA (PI3K)		176
	Target characteristics	176
	Inhibitors in development	177
Future trends		181

Chapter 4 Non-cancer applications of kinase drugs 184

Summary		184
Introduction		185
Chronic inflammation and kinases		185
Leading indications		187
Arthritis		187
Diabetes		195
Inflammation		201
Immunosuppression		205
Ophthalmology		208
Psoriasis		211
Pulmonary diseases		214
Cardiovascular		218
Myelodysplastic disorders		222
GI disorders		227
Pain		229
Leading kinase targets		231
MAPK14		231
	Target characteristics	231
	Inhibitors in development	232
FRAP1		233
	Target characteristics	233
	Inhibitors on the market	233
	Inhibitors in development	234
JAK3		234
Target characteristics		234
	Inhibitors in development	234
NTRK1		234
	Target characteristics	234
	Inhibitors in development	235
ROCK1		235
	Target characteristics	235
	Inhibitors on the market	235
	Inhibitors in development	236

Chapter 5 Leading kinase drug originating companies 238

Summary/Introduction	238
5.1 Abbott Laboratories	239
Company overview	239
Kinase-related collaborations (2005 onwards)	239
Kinase drug pipeline	239

Ambit Biosciences Corp	241
Company overview	241
Kinase-related collaborations (2005 onwards)	241
Kinase drug pipeline	242
Amgen Inc	244
Company overview	244
Kinase-related collaborations (2005 onwards)	244
Kinase drug pipeline	244
Array BioPharma Inc	246
Company overview	246
Kinase-related collaborations (2005 onwards)	246
Kinase drug pipeline	246
AstraZeneca plc	248
Company overview	248
Kinase-related collaborations (2005 onwards)	248
Kinase drug pipeline	249
Avila Therapeutics Inc	251
Company overview	251
Kinase drug pipeline	252
Boehringer Ingelheim GmbH	253
Company overview	253
Kinase-related collaborations (2005 onwards)	253
Kinase drug pipeline	254
Bristol-Myers Squibb Co	256
Company overview	256
Kinase-related collaborations (2005 onwards)	256
Kinase drug pipeline	257
Cephalon Inc	259
Company overview	259
Kinase-related collaborations (2005 onwards)	259
Kinase drug pipeline	259
Deciphera Pharmaceuticals LLC	261
Company overview	261
Kinase-related collaborations (2005 onwards)	261
Kinase drug pipeline	261
Eli Lilly Co	263
Company overview	263
Kinase-related collaborations (2005 onwards)	263
Kinase drug pipeline	264
Exelixis Inc	268
Company overview	268
Kinase-related collaborations (2005 onwards)	268
Kinase drug pipeline	269
GlaxoSmithKline plc	271
Company overview	271
Kinase-related collaborations (2005 onwards)	271
Kinase drug pipeline	272

Hoffmann-La Roche Ltd	274
Company overview	274
Kinase-related collaborations (2005 onwards)	274
Kinase drug pipeline	275
Johnson & Johnson	277
Company overview	277
Kinase-related collaborations (2005 onwards)	277
Kinase drug pipeline	278
Kyowa Hakko Kirin Co Ltd	280
Company overview	280
Kinase-related collaborations (2005 onwards)	280
Kinase drug pipeline	280
Novartis International AG	282
Company overview	282
Kinase-related collaborations (2005 onwards)	282
Kinase drug pipeline	283
Pfizer Inc	286
Company overview	286
Kinase-related collaborations (2005 onwards)	287
Kinase drug pipeline	287
Sanofi-Aventis Group	289
Company overview	289
Kinase drug pipeline	289
Wyeth	291
Company overview	291
Kinase-related collaborations (2005 onwards)	291
Kinase drug pipeline	292

Chapter 6 Market Analysis: Trends and Forecasts 296

Summary	296
Prevalence of targeted diseases	297
Analyses and Forecasts by Type of Agent	299
Limus agents/mTOR inhibitors	303
Overview	303
Standalone mTOR inhibitors	304
Drug-eluting stents	305
Drug-eluting stent market	306
Sirolimus-eluting stents	307
Everolimus- and zotarolimus-eluting stents	307
Sales trends in mTOR inhibitors	308
Forthcoming mTOR inhibitors	308
EGFR Family inhibitors	309
Overview	309

	Trastuzumab	309
	Erlotinib	310
	Cetuximab	310
	Gefitinib	311
	Panitumumab	311
	Lapatinib	311
	Nimotuzumab	312
	Sales trends in EGFR Family inhibitors	312
	Forthcoming EGFR Family Inhibitors	313
ABL/FLT3 Group	Inhibitors	313
	Overview	313
	Imatinib	314
	Dasatinib	314
	Nilotinib	315
	Sales trends in ABL1/FLT3 Family Inhibitors	315
	Forthcoming ABL1/FLT3 Family Inhibitors	315
VEGFR Family		316
	Overview	316
	Sunitinib	317
	Sorafenib	317
	Sales trends in VEGFR Family inhibitors	317
	Forthcoming VEGFR Family Inhibitors	318
Other launched agents		318
	Overview	318
	Fasudil	319
	Pirfenidone	319
	Sales trends of other agents	319
	Other forthcoming agents	320
Company sales and trends		321
Patenting trends		323
Appendix 1 Kinase-related targets and their abbreviations		326
Appendix 2 Other abbreviations and acronyms		329
Appendix 3 Research Methodology		331
Index		332

List of Figures

Figure 1.1:	Leading kinase-targeted drug applications	53
Figure 1.2:	Kinase target landscape	54
Figure 6.3:	Kinase originator market shares	323

List of Tables

Table 1.1:	Human Kinase Gene Audit	29
Table 1.2:	Hanks Classification of Protein Kinases (1995)	34
Table 1.3:	Hanks Classification of Protein Kinases (1995) (continued)	35
Table 1.4:	Kinase Agents by Development Stage	52
Table 1.5:	Kinase Drugs by Product Type	52
Table 1.6:	Leading developers of therapeutic kinase-targeted drugs	53
Table 1.7:	Kinase Agonists and Stimulants	55
Table 3.8:	Kinases implicated in human cancer	82
Table 3.9:	Kinases implicated in human cancer (continued)	83
Table 3.10:	Top 20 Kinase Targets in Cancer	90
Table 3.11:	Overview of ABL1-targeted agents in cancer	98
Table 3.12:	Overview of ABL1-targeted agents in cancer (continued 1)	99
Table 3.13:	Overview of ABL1-targeted agents in cancer (continued 2)	100
Table 3.14:	Overview of EGFR-targeted agents in cancer	109
Table 3.15:	Overview of EGFR-targeted agents in cancer (Phase III and above)	110
Table 3.16:	Overview of EGFR-targeted agents in cancer (Phase II)	111
Table 3.17:	Overview of EGFR-targeted agents in cancer (Phase I)	112
Table 3.18:	Overview of EGFR-targeted agents in cancer (Preclinical)	113
Table 3.19:	Overview of ERBB2-targeted agents in cancer (Phase III and above)	114
Table 3.20:	Overview of ERBB2-targeted agents in cancer (Phase II)	115
Table 3.21:	Overview of ERBB2-targeted agents in cancer (Phase I and Preclinical)	116
Table 3.22:	Overview of FLT3-targeted agents in cancer (Launched)	120
Table 3.23:	Overview of FLT3-targeted agents in cancer (Phase II and III)	121
Table 3.24:	Overview of FLT3-targeted agents in cancer (Phase I and II)	122
Table 3.25:	Overview of FLT3-targeted agents in cancer (Preclinical and Phase I)	123
Table 3.26:	Overview of KIT-targeted agents in cancer	124
Table 3.27:	Overview of KIT-targeted agents in cancer (Continued 1)	125
Table 3.28:	Overview of KIT-targeted agents in cancer (Continued 2)	126
Table 3.29:	Overview of KIT-targeted agents in cancer (Continued 3)	127
Table 3.30:	Overview of KIT-targeted agents in cancer (Continued 4)	128
Table 3.31:	Overview of KIT-targeted agents in cancer (Continued 4)	129
Table 3.32:	Overview of PDGFRA-targeted agents in cancer	130
Table 3.33:	Overview of PDGFRA-targeted agents in cancer (Continued 1)	131
Table 3.34:	Overview of PDGFRA-targeted agents in cancer (Continued 2)	132
Table 3.35:	Overview of PDGFRA-targeted agents in cancer (Continued 3)	133

Table 3.36:	Overview of PDGFRB-targeted agents in cancer (Phase II and Phase III)	134
Table 3.37:	Overview of PDGFRB-targeted agents in cancer (Preclinical and Phase I)	135
Table 3.38:	Overview of FLT1-targeted agents in cancer	139
Table 3.39:	Overview of FLT1-targeted agents in cancer (Continued 1)	140
Table 3.40:	Overview of FLT1-targeted agents in cancer (Continued 2)	141
Table 3.41:	Overview of FLT1-targeted agents in cancer (Continued 3)	142
Table 3.42:	Overview of FLT4-targeted agents in cancer	143
Table 3.43:	Overview of FLT4-targeted agents in cancer (Continued 1)	144
Table 3.44:	Overview of FLT4-targeted agents in cancer (Continued 2)	145
Table 3.45:	Overview of KDR-targeted agents in cancer	146
Table 3.46:	Overview of KDR-targeted agents in cancer (Continued 1)	147
Table 3.47:	Overview of KDR-targeted agents in cancer (Continued 2)	148
Table 3.48:	Overview of KDR-targeted agents in cancer (Continued 3)	149
Table 3.49:	Overview of KDR-targeted agents in cancer (Continued 4)	150
Table 3.50:	Overview of KDR-targeted agents in cancer (Continued 5)	151
Table 3.51:	Overview of JAK2-Targeted Agents in Cancer	153
Table 3.52:	Overview of JAK2-Targeted Agents in Cancer (continued)	154
Table 3.53:	Overview of MET-Targeted Agents in Cancer (continued)	156
Table 3.54:	Overview of MET-Targeted Agents in Cancer (continued)	157
Table 3.55:	Overview of AKT1-Targeted Agents in Cancer (continued)	159
Table 3.56:	Overview of AKT1-Targeted Agents in Cancer (continued)	160
Table 3.57:	Overview of CDC2-Targeted Agents in Cancer	162
Table 3.58:	Overview of CDK2-Targeted Agents in Cancer	163
Table 3.59:	Overview of CDK2-Targeted Agents in Cancer (continued)	164
Table 3.60:	Overview of AURKA-Targeted Agents in Cancer	166
Table 3.61:	Overview of AURKA -Targeted Agents in Cancer (continued)	167
Table 3.62:	Overview of AURKB -Targeted Agents in Cancer	168
Table 3.63:	Overview of PLK1 -Targeted Agents in Cancer	170
Table 3.64:	Overview of FRAP1 -Targeted Agents in Cancer	173
Table 3.65:	Overview of FRAP1 -Targeted Agents in Cancer (Continued 1)	174
Table 3.66:	Overview of FRAP1 -Targeted Agents in Cancer (Continued 2)	175
Table 3.67:	Overview of PIK3CA -Targeted Agents in Cancer	179
Table 3.68:	Overview of PIK3CA -Targeted Agents in Cancer (Continued)	180
Table 4.69:	Kinase-Targeted Agents With Anti-Arthritic Applications	188
Table 4.70:	Kinase-Targeted Agents With Anti-Arthritic Applications (continued 1)	189
Table 4.71:	Kinase-Targeted Agents With Anti-Arthritic Applications (continued 2)	190
Table 4.72:	Kinase-Targeted Agents With Anti-Arthritic Applications (continued 3)	191
Table 4.73:	Kinase-Targeted Agents With Anti-Arthritic Applications (continued 4)	192
Table 4.74:	Kinase-Targeted Agents With Anti-Arthritic Applications (continued 5)	193
Table 4.75:	Kinase-Targeted Agents With Diabetes Applications	198
Table 4.76:	Kinase-Targeted Agents With Diabetes Applications (continued 1)	199
Table 4.77:	Kinase-Targeted Agents With Diabetes Applications (continued 2)	200
Table 4.78:	Kinase-Targeted Agents With Inflammatory Applications	202
Table 4.79:	Kinase-Targeted Agents With Inflammatory Applications (Continued 1)	203
Table 4.80:	Kinase-Targeted Agents With Inflammatory Applications (Continued 2)	204
Table 4.81:	Kinase-Targeted Agents With Immunosuppressive Applications	206
Table 4.82:	Kinase-Targeted Agents With Immunosuppressive Applications (continued)	207
Table 4.83:	Kinase-Targeted Agents With Ophthalmological Applications	209
Table 4.84:	Kinase-Targeted Agents With Ophthalmological Applications (continued)	210
Table 4.85:	Kinase-Targeted Agents With Psoriasis Applications (continued)	212
Table 4.86:	Kinase-Targeted Agents With Psoriasis Applications (continued)	213
Table 4.87:	Kinase-Targeted Agents With Pulmonary Applications (Launched)	215
Table 4.88:	Kinase-Targeted Agents With Pulmonary Applications (Phase I-III)	216

Table 4.89:	Kinase-Targeted Agents With Pulmonary Applications (Preclinical)	217
Table 4.90:	Kinase-targeted agents with cardiovascular applications	220
Table 4.91:	Kinase-targeted agents with cardiovascular applications (continued)	221
Table 4.92:	Kinase-targeted agents with myelodysplastic disorder applications	223
Table 4.93:	Kinase-targeted agents with myelodysplastic disorder applications (continued)	224
Table 4.94:	Kinase-targeted agents with myelodysplastic disorder applications (continued 2)	225
Table 4.95:	Kinase-targeted agents with myelodysplastic disorder applications (continued 3)	226
Table 4.96:	Kinase-targeted agents with GI disorder applications	228
Table 4.97:	Kinase-targeted agents with GI disorder applications	230
Table 5.98:	Overview of Abbott's kinase pipeline by status	240
Table 5.99:	Overview of Ambit Biosciences' Kinase Pipeline by Status	243
Table 5.100:	Overview of Amgen's kinase pipeline by status	245
Table 5.101:	Overview of Array BioPharma's kinase pipeline by status	247
Table 5.102:	Overview of AstraZeneca's kinase pipeline by status	250
Table 5.103:	Overview of Avila Therapeutics' kinase pipeline by status	252
Table 5.104:	Overview of Boehringer Ingelheim's kinase pipeline by status	255
Table 5.105:	Overview of Bristol-Myers Squibb's (BMS) kinase pipeline by status	258
Table 5.106:	Overview of Cephalon's kinase pipeline by status	260
Table 5.107:	Overview of Deciphera Pharmaceuticals' kinase pipeline by status	262
Table 5.108:	Overview of Eli Lilly's kinase pipeline by status	266
Table 5.109:	Overview of Eli Lilly's kinase pipeline by status (continued)	267
Table 5.110:	Overview of Exelixis' kinase pipeline by status	270
Table 5.111:	Overview of Exelixis' kinase pipeline by status	273
Table 5.112:	Overview of Hoffmann-La Roche's kinase pipeline by status	276
Table 5.113:	Overview of Johnson & Johnson's kinase pipeline by status	279
Table 5.114:	Overview of Kyowa Hakko Kirin's kinase pipeline by status	281
Table 5.115:	Overview of Novartis' kinase pipeline by status	284
Table 5.116:	Overview of Novartis' kinase pipeline by status (continued)	285
Table 5.117:	Overview of Pfizer's kinase pipeline by status	288
Table 5.118:	Overview of Sanofi-Aventis' kinase pipeline by status	290
Table 5.119:	Overview of Wyeth's kinase pipeline by status	293
Table 6.120:	World Prevalence Of Diseases	297
Table 6.121:	World Pharma Market by Indication (US\$m), 2008-2013	300
Table 6.122:	World Pharma Market by Region (US\$m), 2008-2013	301
Table 6.123:	Kinase Drug Analysis (in 2007-2008) and Forecasts, 2009-2013 (\$USm)	302
Table 6.124:	Kinase Inhibitors by Geography (\$USm), 2008 and 2013	303
Table 6.125:	Manufacturer Analysis (2008) and Forecasts (US\$m), 2009-2013	322
Table 6.126:	Major Kinase Patent Indications	324
Table 6.127:	Leading Kinase Patent Assignees	325